Medicine evaluation figures

The European Medicines Agency (EMA) publishes information on the volume and outcome of marketing authorisation and post-authorisation applications for human and veterinary medicines that it evaluates. The documents on this page contain factual information on medicines evaluation, presented on an annual and monthly basis.
HumanVeterinaryData on medicinesMedicines

As of January 2023, the overviews containing monthly figures for human medicines also include:

  • new active substances (NAS) status at the time when EMA's Committee for Medicinal Products for Human Use (CHMP) publishes an opinion; 
  • number of applications withdrawn after a first CHMP opinion (e.g. during re-examination);
  • number of opinions on companion diagnostics medical devices.

Please note that the monthly figures listed on this page only cover human medicines. For monthly evaluation figures on veterinary medicines, see the monthly reports of the Committee for Medicinal Products for Veterinary Use (CVMP).

For commentaries and analysis, see EMA's annual reports.

For the main outcomes of the monthly plenary meetings of EMA's seven scientific committees, see Committee highlights.

To find out more on authorisation of medicines, see: 

Annual medicine overviews

Human medicines in 2024

114
New medicines recommended for approval
46
Recommended medicines with new active substance

Veterinary medicines in 2024

25
New medicines recommended for approval
2
Recommended medicines with new active substance

Select the expandable panel below for previous annual medicine overviews (formerly called 'highlights'):

Monthly figures - 2025

Monthly figures - 2024

Monthly figures - 2023

Monthly figures - 2022

Monthly figures - 2021

Monthly figures - 2020

Monthly figures - 2019

Monthly figures - 2018

Monthly figures - 2017

Monthly figures - 2016

Share this page